425: Barinthus Bio Merges with Clywedog Therapeutics

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, with Clywedog stockholders owning approximately 66%.

Summary

• Barinthus Biotherapeutics plc (Beacon) and Clywedog Therapeutics, Inc. (Clywedog) have entered into a definitive merger agreement for an all-stock transaction.
• Upon closing, Clywedog stockholders are expected to own approximately 66% of the combined company, and Beacon shareholders are expected to own approximately 34% on a fully diluted basis.
• The combined company will be renamed Clywedog Therapeutics, Inc. and is expected to trade on the Nasdaq Global Market under the new ticker symbol CLYD.
• The new entity will advance a portfolio of three differentiated, clinical-stage product candidates targeting metabolic and autoimmune diseases: CLY-101 (Type 1 and Type 2 Diabetes), CLY-201 (Type 1 Diabetes), and VTP-1000 (Celiac Disease).
• Four key value-driving clinical data milestones are anticipated within 18 months of the transaction's closing.
• The estimated cash runway for the combined company is projected to extend through 2027.
• A partial tender offer to acquire up to $27,000,000 in shares of Topco Common Stock from former Barinthus Bio shareholders may be commenced prior to the closing.

Sentiment

Score: 7

Explanation: The merger presents a clear strategic direction with a diversified pipeline and extended cash runway, backed by significant investors. While there are inherent risks in clinical development and transaction completion, the overall tone and planned milestones suggest a positive outlook for the combined entity.

Positives

• The merger creates a diversified pipeline with three clinical-stage product candidates targeting high-value indications in Type 1 and Type 2 diabetes and celiac disease.
• Four key value-driving clinical data milestones are expected within 18 months of closing, offering multiple near-term catalysts.
• The estimated cash runway for the combined company extends through 2027, providing financial stability for ongoing development.
• The combined company will be supported by additional investments from existing Clywedog shareholders OrbiMed and Torrey Pines Investment LLC, as well as new investors.
• The leadership team will integrate deep scientific understanding of metabolic and autoimmune spaces with strong clinical development experience.
• CLY-101 shows potential for long-term glucose control in Type 2 Diabetes and restoring insulin production in Type 1 Diabetes, with possible synergistic effects with GLP-1 agonists.
• CLY-201 is a highly-selective TYK2 inhibitor targeting T-cell mediated inflammation, a key factor in Type 1 Diabetes.
• VTP-1000 is a differentiated antigen-specific tolerance immunotherapy for celiac disease, with Phase 1 data expected soon.

Negatives

• Barinthus Bio American Depositary Shares (ADSs) will no longer trade on NASDAQ after the transaction closes.
• The transaction involves a complex UK scheme of arrangement and US merger, which can introduce execution risks.
• There is a potential for unexpected costs, liabilities, or delays in completing the transaction.
• Management's attention may be diverted from ongoing business operations during the pendency of the proposed transaction.
• Restrictions during the pendency of the proposed transaction may impact the ability to pursue certain business opportunities or strategic transactions.

Risks

• The proposed transaction may not be completed in a timely manner or at all, which could adversely affect the businesses of both Clywedog and Barinthus Bio and the price of their respective securities.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction.
• There is a potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction, including stockholder approvals from both companies and the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement.
• The potential failure to satisfy other conditions to the consummation of the transaction, including the completion of the Self-Tender Offer, could prevent closing.
• The proposed transaction may involve unexpected costs, liabilities, or delays.
• The announcement, pendency, or completion of the proposed transaction could affect the ability to attract, motivate, retain, and hire key personnel and maintain relationships with customers, distributors, suppliers, and other business partners.
• The proposed transaction may divert management's attention from ongoing business operations.
• There is a risk of legal proceedings related to the proposed transaction, which could result in expense or delay.
• Clywedog or Barinthus Bio may be adversely affected by other economic, business, and/or competitive factors.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Merger Agreement.
• Restrictions during the pendency of the proposed transaction may impact the ability to pursue certain business opportunities or strategic transactions.
• There is a risk that governmental and regulatory approvals required for the proposed transaction may not be obtained, or that such approvals may delay consummation or result in conditions that reduce anticipated benefits or cause abandonment.
• The anticipated benefits of the proposed transaction may not be fully realized or may take longer to realize than expected.
• The value of the combined company securities to be issued in the proposed transaction is subject to market fluctuations.
• Integration of the proposed transaction post-closing may not occur as anticipated, or the combined company may not achieve the growth prospects expected from the transaction.
• The market price of Barinthus Bio ADSs could be affected by the announcement, pendency, or completion of the proposed transaction.
• Challenges are inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products.
• The scope, progress, results, and costs of developing product candidates, including conducting preclinical studies and clinical trials, are uncertain.
• The timing and costs involved in obtaining and maintaining regulatory approval for current or future product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product, pose risks.
• The market for, adoption, pricing, and reimbursement of product candidates, and the ability to compete with rapidly growing and evolving therapies and procedures, are uncertain.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, or other arrangements, and the performance of third-party suppliers and manufacturers.
• The ability to establish and maintain intellectual property protection for product candidates and products or avoid or defend claims of infringement is a risk.
• Exposure to inflation, currency rate, and interest rate fluctuations, and risks associated with doing business locally and internationally, as well as fluctuations in the market price of Barinthus Bio ADSs, are factors.
• Risks relate to competition within the industry in which each of Clywedog and Barinthus Bio operates.
• The unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities, could have an impact.
• The termination of any of Clywedog's or Barinthus Bio's license agreements and/or collaboration agreements may impact the combined company's ability to license in additional programs in the future and lead to delays or unforeseen costs.

Future Outlook

The combined company, Clywedog Therapeutics, will focus on advancing a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. Four key clinical data milestones are expected within 18 months of the transaction's closing, and the estimated cash runway extends through 2027. The company aims to develop potentially disease-modifying therapies for Type 1 and Type 2 diabetes and celiac disease.

Management Comments

• "We believe that the combination of Barinthus Bio and Clywedog will create immediate value and long-term upside for all stakeholders by diversifying our pipeline and increasing the number of meaningful clinical milestones." Bill Enright, Chief Executive Officer of Barinthus Bio (and future CEO of the combined company).
• "The combined team will bring a deep scientific understanding of metabolic and autoimmune spaces together with strong clinical development experience, positioning us well to execute for patients and shareholders." Bill Enright.
• "I am honored to have the opportunity to lead an exceptional team and am truly excited to advance our highly differentiated pipeline of disease modifying therapies for Type 1 and Type 2 diabetes, and celiac disease." Bill Enright.
• "I am excited to be part of the combined company as we strive to develop potentially disease-modifying therapies for diabetes and autoimmune disorders." Dr. Iain Dukes, Venture Partner at OrbiMed (and future Executive Chairman of Clywedog Therapeutics).

Industry Context

The merger creates a new entity focused on metabolic and autoimmune diseases, a significant and growing therapeutic area. The combined pipeline includes assets like CLY-101, which has potential synergies with blockbuster GLP-1 agonists, indicating an awareness of current market trends in diabetes treatment. The focus on disease-modifying therapies positions the company in a competitive landscape seeking more fundamental treatments beyond symptom management.

Comparison to Industry Standards

• CLY-101's potential to work synergistically with GLP-1 agonists suggests a strategy to complement existing successful diabetes treatments, rather than directly compete, potentially expanding market reach.
• The focus on 'disease-modifying therapies' for diabetes and autoimmune disorders aims for a higher standard of treatment compared to symptomatic relief, aligning with a growing industry trend towards curative or long-term solutions.
• The estimated cash runway through 2027 provides a longer operational window compared to many early-stage biopharmaceutical companies, which often face more immediate financing pressures.

Management Changes

Corporate Governance

Legal Proceedings

• No pending or threatened legal proceedings against Barinthus Bio or its subsidiaries that would have a Beacon Material Adverse Effect, prevent/delay the merger, or delay performance of obligations.
• No pending or threatened legal proceedings against Clywedog or its subsidiaries that would have a Clywedog Material Adverse Effect, prevent/delay the merger, or delay performance of obligations.
• No outstanding orders binding Barinthus Bio or Clywedog.
• Beacon will promptly notify Clywedog of any transaction-related litigation and allow participation in defense and settlement. Beacon will not settle such litigation without Clywedog's prior written consent.

Related Party Transactions

• Certain shareholders of Beacon, holding approximately 25% of the total outstanding share capital, have entered into voting and support deeds with Clywedog.
• Certain stockholders of Clywedog, holding 100% of the voting power, have entered into voting and support agreements with Beacon.
• Certain officers, directors, and shareholders of Clywedog (who will become Topco shareholders) and certain officers and directors of Beacon (who will continue with Topco) have entered into lock-up agreements for a period of six months following the closing date.
• Existing Clywedog shareholders OrbiMed and Torrey Pines Investment LLC will provide additional investments to the combined company.
• Clywedog's Simple Agreements for Future Equity (SAFE Agreements) are expected to convert into Clywedog Common Stock prior to the Merger Effective Time.

Stakeholder Impact

• Shareholders of Barinthus Bio will receive one share of common stock in the new combined company for each ADS or ordinary share owned, and will own approximately 34% of the combined company. Barinthus Bio ADSs will cease trading on NASDAQ.
• Stockholders of Clywedog will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned, and will own approximately 66% of the combined company.
• A partial tender offer of up to $27 million may be commenced for shares of Topco Common Stock held by former Barinthus Bio shareholders.
• Key management from both companies will lead the combined entity, ensuring continuity and leveraging expertise.
• Equity awards (options, restricted share units) from both companies will be converted into Topco equity awards, maintaining employee incentives.
• Existing Clywedog investors (OrbiMed, Torrey Pines Investment LLC) and new investors will provide additional capital, demonstrating confidence in the combined entity's prospects.
• Patients in the metabolic and autoimmune disease areas may benefit from the advancement of a diversified pipeline of clinical-stage product candidates.

Next Steps

• Prepare and file a Registration Statement on Form S-4 with the SEC, including a proxy statement.
• Seek effectiveness of the Registration Statement from the SEC.
• Mail the proxy statement to Beacon's shareholders.
• Obtain approvals from Beacon's shareholders for the Scheme Transaction and related matters, and sanction by the Court of the Scheme Transaction.
• Obtain approval from Clywedog's stockholders for the Merger Agreement, Merger, and Contemplated Transactions.
• Seek Nasdaq listing approval for the shares of Topco Common Stock.
• Obtain certain consents, clearances, and expirations of waiting periods under applicable antitrust laws.
• Complete the Self-Tender Offer if Topco elects to commence it.
• Topco Board to adopt the Topco Equity Incentive Plan and Topco ESPP, subject to shareholder approval.
• File Form S-8 registration statements for the Topco Equity Incentive Plan and Topco ESPP after Merger Effective Time.
• CLY-101 Phase 2A proof of principle study in Type 2 diabetes patients first top-line data readout expected the second half of 2026.
• CLY-101 Phase 2A proof of principle study in Type 1 diabetes (Stage 3) patients first top-line data readout expected the second half of 2026.
• VTP-1000 Topline data from SAD portion of Phase 1 AVALON study expected Q4 2025.
• VTP-1000 Topline data from MAD portion of Phase 1 AVALON study expected in mid-2026.

Key Dates

Recommendation

The merger creates a new entity with a diversified clinical-stage pipeline and an extended cash runway, backed by significant investors. This strategic move aims to create long-term value. However, the transaction is subject to various approvals and inherent risks of clinical development and integration. The immediate impact on Barinthus Bio's share price is likely to be driven by the market's perception of the new combined entity's potential and the terms of the merger, including the ownership split and potential tender offer. Given the forward-looking nature of the benefits and the execution risks, a 'hold' recommendation is appropriate for existing shareholders to observe the closing of the transaction and initial progress of the combined pipeline. New investors might consider waiting for more clarity on the integration and early clinical data milestones.

Keywords

Merger, Biotherapeutics, Diabetes, Celiac Disease, Autoimmune, Metabolic Diseases, Clinical Stage, Drug Development, NASDAQ, CLYD, BRNS, OrbiMed, Torrey Pines, Immunology, Inflammation, Therapeutics